3 Results for "

bortezomib-resistant multiple myeloma

" in MedChemExpress (MCE) Product Catalog:
Products (3)

3 Results for "bortezomib-resistant multiple myeloma" in MCE Product Catalog:

Cat. No.: HY-182314
CAS No.: 3104109-31-8
Target:  

JAK STAT Apoptosis

Research Areas:  

Cancer

JAK3-IN-20 is a selective and orally active JAK3 inhibitor with an IC50 of 0.7473 nM. JAK3-IN-20 forms a covalent bond with JAK3 Cys909, outcompetes ATP for catalytic site binding, and blocks JAK-STAT pathway activation. JAK3-IN-20 inhibits migration, proliferation, and tumor growth of Bortezomib (HY-10227)-resistant cancer cells. JAK3-IN-20 induces dose-dependent apoptosis. JAK3-IN-20 can be used for the research of Bortezomib-resistant multiple myeloma .
loading...
    loading...
Cat. No.: HY-169135
Research Areas:  

Cancer

PROTAC 20S proteasome subunit β5 degrader 2 is a PROTAC degrader targeting the 20S proteasome subunit β5, with a DC50 of 0.16 μM. PROTAC 20S proteasome subunit β5 degrader 2 forms a ternary complex with the CRBN E3 ligase, induces ubiquitination of the 20S proteasome subunit β5, and promotes its degradation via the proteasome. PROTAC 20S proteasome subunit β5 degrader 2 exerts antiproliferative effects in cancer cells and exhibits antitumor activity both in vitro and in vivo. It can be used for the research of pharyngeal cancer and drug-resistant multiple myeloma .
loading...
    loading...
Cat. No.: HY-125542
CAS No.: 2136278-38-9
Purity:  99.73%
Target:  

Apoptosis JAK STAT ERK PI3K Akt

Research Areas:  

Cancer

DCZ3301 is an apoptosis inducer. DCZ3301 modulates JAK2/STAT3, ERK1/2, and PI3K/AKT pathways. DCZ3301 induces G2/M and M phase cell cycle arrest and inhibits cell proliferation and viability. DCZ3301 enhances DNA damage, inhibits DNA repair, and suppresses angiogenesis. DCZ3301 can be used for the research of diffuse large B-cell lymphoma, multiple myeloma and leukemia/lymphoma .
loading...
    loading...